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a10815 AcuteProceduralComplksrtioneAfterRotationalAtherectomyArePredictedByStripChart
Recordings:ReaulteFromSTRATAS
D.S. Eccleston, M.C. Horrigan, R.E. Kuntz, Y.Zhang, K.K.L. Ho, D.E. Cutlip,
P.L.Whitlow for the STRATAS investigators. Cleveland Clinic, C/eve/arrd,
Ohio, USA
Major cnmplicstlons (MC) occur in H% of rotational atheractomy (RA)
oases. STRATAS (Study TOdetermine Rotablator And Transkiminal Angio-
plasty Strategy) has randomized 49zV500patienta to aggressive or stsndard
RA strategies. Strip chart recordings plot burr speed sgainst time to assess
RA technique. Using a multlvariate logistic regression model, we examined
whether dacelerstioni in burr speed (DECEL) or RAduration predicted acute
MC (death, QMI, CABG or repeat PTCA) after correcting for age, sex, dia-
betes, prior Ml, lesion length and calcification. In 279 consecutive patients
with adjudicated outcome date, (mean age 63.1 * 10.6 years, 25.9°A di-
abetic, mean LVEF 56 * 1lYo) cumulative DECEL > 7,000 RPM for z 5
semndsindependentlypredictedissection(p< 0.02)andin-hospitalMC
(p < 0.01). Longer RA time was also associated with MC; however even
in those with long RA times (> 300s), DECEL still predicted MC (p= 0.03)
(Table). Conclusion: Optimizing RAtachnique by using strip chart recordings
to avoid decelerations in burr speed may reduce the incidence of dissection
and major complications with rotational atherectomy.
PredictoraofMajorCompllcatlons p (n= 279)
Dacelsrstionsz 5000RPM>5 *C 0.049
Deeslsrations>7000 RPM>5 sec 0.020
Maximum mean deceleration 0.25
Mean time per fun 0.31
Total RAtime >300 sac 0.020
D10816 TheInfluenceofAdjunctBalloonafterDirectionalCoronaryAtherectomy
Satoru Sumitsuji, Etsuo Tsuchikane, Atsunori Fukuhars, Yumiko Nakagawa,
Harumasa Yasuda, Taizo Hiraishi, Tohru Kobayashi. Osaka Medics/ Cerrtec
Osaka, Japsn
It is well known that a large acute gain wea obtainad by adjunct balloon (AB)
after DCA. The purpose of thie study wae to clarify the influence of adjunct
balloon after DCA at follow-up. We examined 125 lesions in 120 casea. To
clarify the effect of adjunct balloon and its chronic influence, we performed
eerial IVUS study (at preDCA, poetDCA, post sdjunet balloon and follow-up).
125 lesions were divided into two groups (1) no adjunct balloon group (DCA
group), (2) adjunct balloon group (AB group). Veaael area (VA), plaque area
(PA) and lumen area (LA) were meaeurad. Late lose was calculated as LA at
follow-up - IA at post DCA in the DCA group, LA at follow-up - LA at post
adjunct balloon in the AB group. LA at follow-up, late loss, decreaee of VA
and increase of PA at follow-up were compared with the DCA group and the
AB group.
Reaults:
DCA group(mm2 AB group (mmz)
w at postDCAJAB B.?& 3.7 tO.3 + 7.6 p~0.01
M at follow-up S.6 TkS.7 6.3 l 4.1 p = n.s
Late 10ss –2.0+ 2.6 –3,9 l 3.6 p 50.01
Decrease of VA –1.1 +3.0 –1.s *3.O p = n.s
Increase or PA 0.9 +2.4 l.e *4.6 p = 0.07
Conclusions: (1) Adjunct balloon results in a larger lumen area after
intervention. (2) However, lumen area decreases more after adjunct balloon
than after DCA alone, and IA at follow-up in these two groups shows no
significant difference.
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L!!z!2z‘bciximabmorea=sboththe’no’denceandMagnitudeof CreatineKinaseElevationDuring
RotationalAtherectomy
G.A. Braden, R.J. Applegate, T.M. Young, W.W. Love, D.C. Sane. The
Bowman Grey School of Medicine, Wake Forest Univemify Wkrston-Sa/em,
NC, USA
Rotational Athersotomy (PTCRA) has been aesooiated with increases in
creatine kinase (CK) levels. Although the mechanism remaine uncertain,
platelet activation hae been shown to ocour during aggressive athersctomy.
Abciximab (ReoPro) attenuates CK elevations from DCA and high risk bal-
loon angioplasty. Therefore, we prospectively aeseseed the effect of Rao-
Pro In patients undergoing PTCRA: 100 patients received standard ReoPro
treatment in addition to aapirirrlheparin. The control group consisted of 100
patients treated with aspirirVheparin therapy without RaoPro. There were
no differences in the indication for PTCRA (ReoPro vs. Control): unstable
angina: 56% vs. 57%, post Ml ischemia: 12% vs. 7%, stable angina: 15%
vs. 8% and restenosis: 17°Avs. 28%, or vessels treated. Veasel complexity
wee worse in the RsoPro group (B2/C lesions: 77% vs. 59%, p < 0.01) and
more burrs were used (2.3 + 0.1 vs 1.9 + 0.1 p < 0.01). There waa a trend
towards increased stentlng in the mntrol group: (14% vs 23Y0, p = 0.10).
Complications were similar: (ReoPro vs control), CABG: O%vs 1%, Q-wave
Ml: O%vs O%,death: O%vs O%,bleeding: 2% vs O%(p = NS). CK analyaea
were as follows.
PeakCK CKhe 1-3xNL > 3XNL AnvAbn.CK
ReoPro t45 + 13 89& 18 to% 3% t3%
Control 238 *20 773 *45 17% 9“70 264A
P value 0,02 0.03 0.15 0.07 0.02
Conclusion: Despite more complex Iesione requiring the uee of more
burrs, RaoPro decreased abeolute CK rise by 46%, the incidence of any
abnormal CK rise by 50%, and the occurrence of non-Q wave Mls by 67Y0.
These findinge demonstrate that CK rises following rotational atherecromy
are platelet mediated and can be substantially reduced with ReoPro.
m Abci.imeb(c~E~)andAn9,09raPhicRestenoeis
AfterCoronaryStentPlacement
J. Hausleiter, H. Schiihlen, H. Walter, S. Elezi, M. Hadamitzky,
J. Dirschinger, F.-J.Neumann, A. Schbmig. Deutscfrea Ffarzzentrurn
Miinchen & 1.Medizinische Klinik, TechnischaUniversitat, Munich,
Germany
The frequency of clinical restenoais after balloon angioplasty hae been sig-
nificantly reduced by the administration of abciximab (ReoPro’”, Lilly). In the
present retrospective analysis we studied the impact of pen- and postproce-
dural abciximab on angiographic restenoeis after coronary stent placement.
Between April ’95 and January ‘96abciximab wasadministerad in 66 patients
forintracoronary thrombusformation during astentplacement procedure. An-
giographic 6-month follow-up is available for 67 lesions in 50 patients (78%
of eligible patients). A control group of 67 lesions was matched for eteno-
eis localization, vessel diameter, number of stente implanted, preeence of
total occlusion, thrombue before PTCA, residual dissection after stenting,
concomitant antithrombotic medication, sex and age. Comparing the two
groups there were no significant differences in procedural and angiographic
variables at the time of stent placement. Restenosis was defined as a Y. di-
ameter stenosis ? 50%. The results of the 6-month quantitative angiographic
results were:
Abciximab Control p-value
Min. Iuminal diameter (mm) 1.s4• 0.s2 1.84 + 0.63 ns
Reference diameter (rnm) 3.03 * 0.4s 3.01 * 0.50 ns
Late lumen Ioea (mm) 1,19 * 0.s3 1.19 + 0.84 ns
% Diameter stenoais 39.9 + 24.6 39. t + 25.0 ns
Reslenosis rate (“A) 26.5 29.4 ns
Conclusions.’Data from this retrospective analysis do not suggest that pa-
tients receiving pafi- and postprocedural abciximab for intracoronary throm-
bus formation have a more fsvorable angiographic outcome 6 months after
coronary stent placement.
